Lindenwold Advisors Biogen Inc. Transaction History

Lindenwold Advisors

$198 Million
Q3 2024

A detailed history of Lindenwold Advisors transactions in Biogen Inc. stock. As of the latest transaction made, Lindenwold Advisors holds 4,605 shares of BIIB stock, worth $686,237. This represents 0.45% of its overall portfolio holdings.

Number of Shares

4,605

Previous 4,550 1.21%

Holding current value

$686,237

Previous $1.05 Million 15.37%

% of portfolio

0.45%

Previous 0.56%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$189.07 - $236.8 $10,398 - $13,024	55 Added 1.21%	4,605 $892,000
Q2 2024 Aug 13, 2024	BUY	$190.52 - $236.72 $5,715 - $7,101	30 Added 0.66%	4,550 $1.05 Million
Q1 2024 May 09, 2024	BUY	$212.02 - $267.71 $347,712 - $439,044	1,640 Added 56.94%	4,520 $974,000
Q4 2023 Feb 08, 2024	SELL	$222.59 - $267.94 $401,552 - $483,363	-1,804 Reduced 38.51%	2,880 $745,000
Q3 2023 Oct 19, 2023	BUY	$253.3 - $285.89 $7,345 - $8,290	29 Added 0.62%	4,684 $1.2 Million
Q2 2023 Aug 07, 2023	SELL	$275.25 - $318.06 $232,586 - $268,760	-845 Reduced 15.36%	4,655 $1.33 Million
Q1 2023 May 05, 2023	BUY	$256.56 - $292.34 $17,959 - $20,463	70 Added 1.29%	5,500 $1.53 Million
Q4 2022 Feb 13, 2023	BUY	$252.44 - $306.72 $13,631 - $16,562	54 Added 1.0%	5,430 $1.5 Million
Q3 2022 Oct 28, 2022	BUY	$194.69 - $268.46 $7,398 - $10,201	38 Added 0.71%	5,376 $1.44 Million
Q2 2022 Aug 05, 2022	BUY	$187.54 - $223.02 $5,813 - $6,913	31 Added 0.58%	5,338 $1.09 Million
Q1 2022 May 09, 2022	BUY	$193.77 - $244.14 $40,497 - $51,025	209 Added 4.1%	5,307 $1.12 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $1.14 Million - $1.47 Million	5,098 New	5,098 $1.22 Million

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindenwold Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Lindenwold Advisors with notifications on news.

Account

Lindenwold Advisors Biogen Inc. Transaction History